2552 Stock Overview
Engages in the development and commercialization of drugs for the treatment of diabetes in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Hua Medicine (Shanghai) Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.95 |
| 52 Week High | HK$2.79 |
| 52 Week Low | HK$1.03 |
| Beta | 1.35 |
| 1 Month Change | -4.41% |
| 3 Month Change | 27.45% |
| 1 Year Change | 27.45% |
| 3 Year Change | -49.09% |
| 5 Year Change | -63.14% |
| Change since IPO | -76.45% |
Recent News & Updates
Recent updates
Hua Medicine (Shanghai) Ltd. (HKG:2552) Investors Are Less Pessimistic Than Expected
Mar 28
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Shareholder Returns
| 2552 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -12.2% | -2.5% | 2.1% |
| 1Y | 27.5% | 5.2% | 12.6% |
Return vs Industry: 2552 exceeded the Hong Kong Pharmaceuticals industry which returned 4.1% over the past year.
Return vs Market: 2552 exceeded the Hong Kong Market which returned 13% over the past year.
Price Volatility
| 2552 volatility | |
|---|---|
| 2552 Average Weekly Movement | 16.5% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2552's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2552's weekly volatility has increased from 11% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 168 | Li Chen | www.huamedicine.com |
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease.
Hua Medicine (Shanghai) Ltd. Fundamentals Summary
| 2552 fundamental statistics | |
|---|---|
| Market cap | HK$1.92b |
| Earnings (TTM) | -HK$270.76m |
| Revenue (TTM) | HK$276.98m |
6.9x
P/S Ratio-7.1x
P/E RatioIs 2552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2552 income statement (TTM) | |
|---|---|
| Revenue | CN¥255.89m |
| Cost of Revenue | CN¥131.17m |
| Gross Profit | CN¥124.72m |
| Other Expenses | CN¥374.87m |
| Earnings | -CN¥250.14m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 48.74% |
| Net Profit Margin | -97.75% |
| Debt/Equity Ratio | -175.0% |
How did 2552 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 04:48 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hua Medicine (Shanghai) Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CLSA |
| Bo Li | CLSA |
| Ziyi Chen | Goldman Sachs |